Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SEI
|
|||
| Former ID |
DAP000335
|
|||
| Drug Name |
Levocabastine
|
|||
| Synonyms |
Levocabastin; Levocabastina; Levocabastinum; Livostin; Levocabastina [Spanish]; Levocabastinum [Latin]; Levocabastine (INN); Levocabastine [INN:BAN]; Livostin (TN); (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid; 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic conjunctivitis [ICD-11: 9A60.02; ICD-10: H10.1] | Approved | [1], [2] | |
| Therapeutic Class |
Antiallergic Agents
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H29FN2O2
|
|||
| Canonical SMILES |
CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23?,25?,26-/m1/s1
|
|||
| InChIKey |
ZCGOMHNNNFPNMX-YHYDXASRSA-N
|
|||
| CAS Number |
CAS 79449-98-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979772, 11467067, 11468187, 11486844, 14807001, 15501039, 32961388, 34718386, 46505909, 47349573, 47573562, 47646743, 47795244, 49699381, 50065214, 50123948, 50473844, 57313613, 85788903, 96024807, 104304776, 124893604, 126666083, 134221875, 134337647, 135257219, 135650515, 136081779, 137005452, 137263743, 160964440, 163693550, 163852910, 175265815, 176484508, 179116755, 180191810, 194168802, 198974741, 223532782, 223681847, 226396552, 226517688, 242042090, 248745270
|
|||
| ChEBI ID |
CHEBI:92584
|
|||
| ADReCS Drug ID | BADD_D01270 | |||
| SuperDrug ATC ID |
R01AC02; S01GX02
|
|||
| SuperDrug CAS ID |
cas=079516680
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1586). | |||
| REF 2 | Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. | |||
| REF 3 | Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62. | |||
| REF 4 | Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.